WO2007098090A3 - Treatment of hyperproliferative diseases with n-oxides of estrogen receptor modulators - Google Patents

Treatment of hyperproliferative diseases with n-oxides of estrogen receptor modulators Download PDF

Info

Publication number
WO2007098090A3
WO2007098090A3 PCT/US2007/004251 US2007004251W WO2007098090A3 WO 2007098090 A3 WO2007098090 A3 WO 2007098090A3 US 2007004251 W US2007004251 W US 2007004251W WO 2007098090 A3 WO2007098090 A3 WO 2007098090A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxides
estrogen receptor
treatment
receptor modulators
hyperproliferative diseases
Prior art date
Application number
PCT/US2007/004251
Other languages
French (fr)
Other versions
WO2007098090A2 (en
Inventor
John G Curd
John F W Keana
Alshad S Lalani
Paul B Westberg
Original Assignee
Novacea Inc
John G Curd
John F W Keana
Alshad S Lalani
Paul B Westberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacea Inc, John G Curd, John F W Keana, Alshad S Lalani, Paul B Westberg filed Critical Novacea Inc
Publication of WO2007098090A2 publication Critical patent/WO2007098090A2/en
Publication of WO2007098090A3 publication Critical patent/WO2007098090A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to N-oxides of tamoxifen analogs having activity for treating hyperproliferative disorders. Pharmaceutical compositions comprising therapeutically effective amount of an N-oxide of an estrogen receptor modulator, or a pharmaceutically acceptable salt or prodrug thereof, are disclosed. Further, the invention relates to methods of using the compounds, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders.
PCT/US2007/004251 2006-02-17 2007-02-20 Treatment of hyperproliferative diseases with n-oxides of estrogen receptor modulators WO2007098090A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77423206P 2006-02-17 2006-02-17
US60/774,232 2006-02-17

Publications (2)

Publication Number Publication Date
WO2007098090A2 WO2007098090A2 (en) 2007-08-30
WO2007098090A3 true WO2007098090A3 (en) 2008-11-27

Family

ID=38437915

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/004251 WO2007098090A2 (en) 2006-02-17 2007-02-20 Treatment of hyperproliferative diseases with n-oxides of estrogen receptor modulators

Country Status (1)

Country Link
WO (1) WO2007098090A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101637473B (en) * 2009-06-19 2011-08-17 山东大学 Drug combination containing raloxifene and application thereof
ES2627692T3 (en) 2010-06-10 2017-07-31 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
KR101304536B1 (en) 2011-06-03 2013-09-24 전남대학교산학협력단 A composition for treating or preventing liver failure comprising 4-hydroxy tamoxifen analog or pharmaceutically acceptable salts thereof as an effective ingredient
CA2857057A1 (en) 2011-12-14 2013-06-20 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083990A (en) * 1997-04-02 2000-07-04 Pharmos Corporation Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083990A (en) * 1997-04-02 2000-07-04 Pharmos Corporation Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] BATES ET AL.: "Metabolism of tamoxifen by isolated rat hepatocytes", accession no. STN Database accession no. (97:193310) *
DATABASE CAPLUS [online] BENKO ET AL.: "1-P-beta-diethylaminoethoxyphenyl0 1,2-diphenyl-2-chloroethylene N-oxide and its pharmaceutical salts", accession no. STN Database accession no. (103:141610) *
DATABASE CAPLUS [online] MCCAGUE ET AL.: "Metabolism of the 4-iodo derivative of tzmoxifen by isolated rate hepatocytes...", accession no. STN Database accession no. (114:74644) *
DATABASE CAPLUS [online] RUENITZ P.C.: "Rabbit liver microsomal metabolism of enclomiphene", accession no. STN Database accession no. (96:28821) *
DATABASE CAPLUS [online] STEINER ET AL.: "A method for chemoprevention of prostat cancer using toremifene or an analog of metabolite thereof", accession no. STN Database accession no. (131:317768) *
DATABASE CAPLUS [online] UMEMOTO ET AL.: "Tamoxifen-DNA adducts formed by alpha-acetoxytamofixen n-oxide", accession no. STN Database accession no. (132:18545) *
JONES R.M. ET AL.: "Toremifene metabolism in rat, mouse and human liver microsomes: Identification of alpha-hydroxytoremifene by LC-MS", BIOMEDICAL CHROMATOGRAPHY, vol. 16, no. 5, 2002, pages 361 - 363, XP009026516 *

Also Published As

Publication number Publication date
WO2007098090A2 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2007095389A3 (en) Treatment of hyperproliferative diseases with camptothecine n-oxide and analogs
WO2007098089A3 (en) Treatment of hyperproliferative diseases with methotrexate n-oxide and analogs
EP2562177A3 (en) Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof
WO2007087468A3 (en) Adiponectin for treatment of various disorders
WO2007112352A3 (en) Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
MX2010005931A (en) Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same.
WO2008054544A3 (en) Method for delivery across the blood brain barrier
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2008050329A3 (en) Novel sirnas and methods of use thereof
HK1120441A1 (en) Drugs for treatment of ovarian cancer
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2008118141A3 (en) Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
WO2007112357A3 (en) Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
WO2010081091A3 (en) Therapeutic compositions for treatment of corneal disorders
WO2009040666A3 (en) Treatment of graft-versus-host disease
WO2005115432A3 (en) Treatment of ocular diseases and disorders using lantibiotic compositions
WO2008090287A3 (en) Use of at least one botulism neurotoxin for treating the pain induced by therapeutic treatments for the aids virus
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
WO2010053861A3 (en) Biologically active amides
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2007092469A3 (en) Combination of organic compounds
MX2007010886A (en) Acarbose methods and formulations for treating chronic constipation.
WO2007098090A3 (en) Treatment of hyperproliferative diseases with n-oxides of estrogen receptor modulators

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07751040

Country of ref document: EP

Kind code of ref document: A2